Panels

Strategies for Survival and Pipeline Development in the Changing Healthcare Landscape

We are witnessing the transformation of the medical device and pharmaceutical industry before our eyes. In little over a year, we have seen the consolidation of multi-billion players Wyeth – Pfizer, Merck – Schering Plough, and Genentech – Roche. On the diversification front, Johnson & Johnson and Abbott have aggressively pursued new lines of business in the consumer health care and medical devices arena over the last few years. Diversification, consolidation, licensing, joint venture, capital raises and more – what are the growth and survival options available to various industry players and what does this indicate for the future landscape of health care? Furthermore, what effect has the economic downturn had on pipeline development and financing options for biotech and medical device companies? The panel will discuss these strategic questions from the perspective of large and small companies in the space as well as the venture capital community. Panelists will describe the potential implications of health care reform on medical innovation and the role that current medical challenges and market demand play in addressing pipeline development strategies.

Moderator & Panelist Bios

	Moderator: Nurry Hong Mr. Hong joined L.E.K. in 2000 and is a specialist in Life Sciences. He has advised companies across pharmaceuticals, biotechnology, medical devices, diagnostics and services. He has extensive experience in corporate strategy, portfolio planning and optimization, and transaction support.

	Panelist: Joseph Hammang, PhD Mr. Hammang is Sr. Director of Worldwide Science Policy for Pfizer Inc. leading the scholarship and development of internal and industry-leading policy positions. He holds a Ph.D. in Neuroscience, and has held a number of previous positions in the pharmaceutical industry and in state government.

	Panelist: Lisa Suennen Ms. Suennen is a co-founder and Managing Member of Psilos Group, a healthcare-focused venture capital firm with over $577 million under management. Ms Suennen heads Psilos' West Coast office and focuses on the medical device, healthcare information technology and healthcare services sectors. She serves as a Director on the Board of several Psilos portfolio companies.

	Panelist: Andrew Hindman, MBA Mr. Hindman is VP of Corporate Development at Onyx Pharmaceuticals leading corporate development transactions, including the recent acquisition of Proteolix. At Gilead, he served in several roles including the global product launch of Hespera and the merger with NeXstar. He holds an MBA from Columbia, a BA in Biochemistry and Economics from Wesleyan.